

Merck Sharp & Dohme (New Zealand) Limited  
Level 3, 123 Carlton Gore Road  
Newmarket, Auckland 1023  
PO Box 99851, 1149  
New Zealand



7 February 2025

Dear Customer,

**Re: OncoTICE® Mycobacterium bovis (Bacillus Calmette and Guerin (BCG) strain)**

Further to our letter on 10<sup>th</sup> December 2024, we would like to remind you about the on-going reduced availability of OncoTICE and update you in relation to the ordering process we have in place. Based on increased level of demand, MSD is currently on a reduced supply (allocation) in all markets where the medicine is registered, including New Zealand.

Please note: that there are some refinements to the process that was communicated by MSD in December as follows:

To order OncoTICE, hospital pharmacists will contact their preferred wholesaler **via email only** (Not electronic EDI), on the first day of each month. Please note that you will only be able to place your order through one wholesaler. The subject will need to state '**NZ OncoTICE Allocation**', then provide the number of boxes requested and the hospital name. However, this is a request only and does not mean you will receive the quantity requested, as your monthly allocation will be determined by the wholesaler based on historical demand as a portion of the supply available.

Your wholesaler will consolidate all requests and send them to MSD for approval. MSD will then provide the wholesaler with a monthly allocation of OncoTICE, to place their order with HCL. Once the wholesaler receives their delivery of OncoTICE, you will be shipped your monthly allocation.

MSD is putting these measures in place to maximise equitable distribution for patients who require this treatment. Please note that the product has a relatively short shelf life. Please consider this when ordering as MSD would like to ensure that no product is left unused by patients.

For supply/ order enquiries please contact your preferred wholesaler for OncoTICE. For medical enquiries, please contact MSD Medical Information on 0800 500 673. Before prescribing the product, please read the New Zealand Data Sheet:  
<https://www.medsafe.govt.nz/profs/datasheet/o/oncoticeinj.pdf>

Sincerely yours,

A handwritten signature in black ink, appearing to read 'Lilie', is positioned above the printed name.

Dr Lilie Herawati MPH  
Associate Medical Director, Oncology

**NZ-NON-00471** Issued: February 2025

Copyright © 2025 Merck & Co., Inc. Rahway, NJ, USA, and its affiliates. All rights reserved.

If you require information on MSD's privacy policy, please visit <https://www.msdprivacy.com/nz/en/>